Biodesign Institute

袁吉锋 厦门大学生命科学学院  教授 NO.01 个人介绍 袁吉锋，厦门大学生命科学学院闽江学者特聘教授，研究方向围绕“微生物合成生物学”的主线，开发小分子、蛋白多肽类的高效生物合成技术，以解决健康、能源和可持续发展等领域的重大挑战。 担任Biotechnology for Biofuels and Bioprodducts副主编、Microbial Cell Factories副主编、BioDesign Research副主编，中国生物工程学会青年工作委员会委员。 NO.02 研究方向与成果 目前课题组已开发了一系列代谢调控的新策略，创制了多条新颖的生物合成途径，并工程化改造了多种微生物用于疾病诊断和益生菌治疗；近五年在Biosensor and Bioelectronics、Cell Reports Methods、Natural Product Reports、ACS Synthetic Biology等国际知名期刊发表36篇（其中：通讯作者34篇，中科院分区TOP期刊20篇），撰写两个Elsevier章节，申请发明专利20项并获批6项，荣获2022年厦门大学“田昭武学科交叉奖”一等奖；近五年主持包括国家自然科学基金面上项目、企业委托合作项目等6项，累计到位经费约500万元。 NO.03 代表论文 *仅举例其中5篇 1. Anqi Chen*, Jifeng Yuan*. Fermentation utilizing engineered microbes: revolutionizing the production of commercial products from plant-derived bioactive compounds. Elsevier, Book Chapter, 2024, 153-201 2. Bixia Fu#, Cheng Cheng#, Jianqian Fan, Jifeng Yuan*. Designing and engineering synthetic microbiota to utilize plant lignin-based biomass for the synthesis of bioactive compounds. Elsevier, Book Chapter, 2024, 89-124 3. Haofeng Chen, Shan Jiang, Kaixuan Xu, Ziyu Ding, Jiangkai Wang, Mingfeng Cao*, Jifeng Yuan*. Design of thermo-responsive genetic controls with minimal heat-shock response. ACS Synthetic Biology, 2024, Under review 4. Peiling Wu, Ding Luo, Yuezhou Wang, Xiaoxu Shang, Binju Wang, Xianming Deng, Jifeng Yuan*. A two-step enzymatic cascade for synthesis of diverse Ephedra-type alkaloids. Green Chemistry, 2024, Submitted 5. Wenhao Xia, Yongbin Chen, Fengxing Yu, Xiaoyu Wei, Zhen Chen, Jifeng Yuan, Mingfeng Cao*, Ning He*. Cell-free expression system: from basic research to engineering application. Biotechnology Advances, 2024, Under review *点击图片，跳转会议推文 FUZHOU  2024第一届合成生物技术与智能生物制造学术交流会 暨中国微生物学会生化过程模型化与控制专业委员会年会 *上下滑动，查看更多议程 点击“阅读原文”，查看更多精彩内容~

杨世辉 湖北大学生命科学学院  教授 省部共建生物催化与酶工程国家重点实验室  副主任 NO.01 职务介绍 杨世辉，博士，湖北大学教授，博士生导师，省部共建生物催化与酶工程国家重点实验室副主任，湖北省“楚天学者”特聘教授及湖北省“百人计划”创新人才；武汉睿嘉康生物科技有限公司创始人；中国生物发酵产业协会理事会理事，中国化工学会生物化工专委会委员，中国微生物协会分子微生物学及生物工程专业委员会委员，全国技术产品文件标准化技术委员会第二届通用规则分技术委员会委员；湖北省合成生物学学会副理事长兼秘书长。 NO.02 学术经历与成果 毕业于湖北大，武汉大学，及美国加州大学河滨分校。曾先后任职美国能源部橡树岭国家实验室及美国国家可再生能源实验室。 2016年底加入湖北大学生命科学学院，主要从事微生物系统与合成生物学以及绿色生物制造等方面研究；科技部合成生物学重点研发计划“工业菌株重编程优化及应用”项目负责人，主持包括科技部合成生物学重点研发计划、自然科学基金面上与联合项目等多项国家及省部级项目；先后在Nature Biotechnology、Trends in Biotechnology、PNAS、Nucleic Acids Research等期刊发表论文 120多篇，引用5100余次，H-index 40。 获美国授权发明专利7项、中国发明专利授权23项、专利转让17。担任Biodesign Research共同执行主编及《合成生物学》与《生物工程学报》等期刊编辑与编委。 NO.03 代表论文 *仅举例其中5篇 1. Yang Q, Yang Y, Tang Y, Wang X, Chen Y, Shen W, Zhan Y, Gao J, Wu B, He M, Chen S, Yang S*. (2020) Development and characterization of acidic–pH tolerant mutants of Zymomonas mobilis through adaptation and next generation sequencing based genome resequencing and RNA–Seq. Biotechnology for Biofuels 13, 144. 2. Li R, Jin M, Du J, Li M, Chen S, Yang S*. (2020) The magnesium concentration in yeast extracts is a major determinant affecting ethanol fermentation performance of Zymomonas mobilis. Frontiers in Bioengineering and Biotechnology. 8, 957. 3. Qiu M, Shen W, Yan X, He Q, Cai D, Chen S, Wei H, Knoshaug EP, Zhang, M, Himmel ME, Yang S*. (2020) Metabolic engineering of Zymomonas mobilis for anaerobic isobutanol production. Biotechnology for Biofuels 13,15. 4. Yang S*, Franden MA, Wang X, Chou YC, Hu Y, Brown SD, Pienkos PT, Zhang M*. (2020). Transcriptomic profiles of Zymomonas mobilis 8b to furfural acute and long-term stress in both glucose and xylose conditions. Frontiers in Microbiology 11, 13–13. 5. Hu L, Yang Y, Yan X, Zhang T, Xiang J, Gao Z, Chen Y, Yang S*, Fei Q*. (2020). Molecular mechanism associated with the impact of methane/oxygen gas supply ratios on cell growth of Methylomicrobium buryatense 5GB1 through RNA-Seq. Frontiers in Bioengineering and Biotechnology 8, 263. *点击图片，跳转会议推文 FUZHOU  2024第一届合成生物技术与智能生物制造学术交流会 暨中国微生物学会生化过程模型化与控制专业委员会年会 *上下滑动，查看更多议程 点击“阅读原文”，查看更多精彩内容~

The new screening method is designed to use antigens to evaluate multiple disease markers, assess several samples simultaneously, and deliver results in 24 hours The MISPA platform is designed to assess several disease factors at once. (Credit: National Cancer Institute on Unsplash) Researchers at the Arizona State University (ASU) Biodesign Institute have created a new blood-based testing platform dubbed Multiplexed In-Solution Protein Array (MISPA), to accelerate disease detection. The new screening method is designed to evaluate hundreds of disease markers, simultaneously assess thousands of samples, and deliver most results within a day. The platform utilises full-length, folded proteins known as antigens that are each tagged with a unique DNA strand. These proteins detect and attach to antibodies that the immune system produces to fight infection. According to ASU, the method can speed up, improve accuracy, and broaden population-wide disease monitoring as well as individual diagnosis. The MISPA platform is said to be suitable for a wide range of uses, including monitoring infectious disease outbreaks, understanding population immunology, and measuring vaccination efforts. It also has improved versatility, stability, and testing capacity in comparison to traditional procedures, the university said. Biodesign Institute executive director Joshua LaBaer said: “There are number of medical scenarios where doctors need to test for multiple possible disease exposures to deliver the best care. “One example would be pregnancy. Currently, this requires drawing multiple tubes of blood and conducting many separate tests. “So we were looking to create a reliable and reproducible test that could evaluate all those exposures at once and only require a drop of blood. This technology will allow us to get there.” In a proof-of-concept study conducted on students and employees at all ASU campuses, MISPA successfully detected responses to 39 types of bacteria and 99 viruses in more than 2,400 people. The trial was completed in two rounds, spaced six months apart, to track the consistency of the immune response in individuals and to identify any variations due to infections or vaccinations. Additionally, immune responses were constant when participant data was gathered again six months later, which is important for monitoring changes brought on by clinical events. For a single run, MISPA’s present configuration allows for the analysis of up to 200 different antigens in 2,000 samples. The researchers plan to increase this capacity through future developments.